Brief: Kancera Reports Positive Results From Fractal Study

Novakand Pharma AB

20/12/2023 08:05

Dec 20 (Reuters) - Kancera AB  KANC.ST :
    * KANCERA REPORTS POSITIVE TOP LINE RESULTS FROM THE FRACTAL
STUDY
    * STUDY MET PRIMARY OBJECTIVE TO CONFIRM FAVOURABLE SAFETY
AND
TOLERABILITY PROFILE OF KAND567 IN MYOCARDIAL INFARCTION
PATIENTS
    * SECONDARY OBJECTIVE TO DEMONSTRATE SIGNALS OF CLINICALLY
RELEVANT CARDIO-PROTECTIVE EFFECTS WAS MET
    * TAKES ACTION TO CONTINUE DEVELOPMENT OF KAND567 FOR
TREATMENT OF
CARDIOVASCULAR DISEASES
    * WILL INTENSIFY ITS BUSINESS DEVELOPMENT ACTIVITIES WITH
OBJECTIVE TO ENTER INTO A PARTNERSHIP FOR CONTINUED DEVELOPMENT
OF KAND567 FOR TREATMENT OF CARDIOVASCULAR DISEASES

Source text for Eikon:  ID:nMFN1F3Kx2 
Further company coverage:  KANC.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))